Against a backdrop of renewed circulation of the chikungunya virus (CHIKV) since the summer of 2024 on the island of La Réunion, the French High Council for Public Health (HCSP) is issuing recommendations on the safety of products derived from the human body with regard to this agent during epidemic periods. After considering the context and international recommendations, in particular those issued by the European Centre for Disease Prevention and Control (ECDC) following a CHIKV epidemic in Italy in 2017, the HCSP recommends that blood products from donors visiting or coming from areas where active cases of chikungunya have been identified should either be temporarily deferred for 28 days on return from their stay, or undergo blood genomic screening for CHIKV. For organ, tissue or cell donation’s candidates, the HCSP recommends that a genomic test for CHIKV RNA (possibly combined with other genomic tests in the event of co-circulation of several arboviruses) and a serological determination of anti-CHIKV antibodies belonging to the IgM class be carried out in parallel, if possible before the transplant. Decision-making algorithms are available for living and deceased organ donations. For gamete donations during a confirmed epidemic period, donors are either rejected or subjected to a CHIKV genomic test. For all products derived from the human body, the HCSP recommends that the benefit-risk balance for the patient be considered, given that no case of CHIKV transmission has been reported to date following the administration of any product derived from a subject infected with CHIKV. Finally, the HCSP points out that candidates for the donation of blood, organs, tissues or cells who have been vaccinated with a live attenuated anti-CHIKV vaccine are disqualified for a period of 4 weeks following the date of vaccination.